Corneal Cross-Linking
Corneal Cross-Linking (CXL) is a minimally invasive outpatient procedure used to halt the progression of keratoconus and other forms of corneal ectasia, including post-LASIK ectasia (post ectopic ectasia). This innovative treatment works by strengthening the cornea through the formation of new chemical bonds between collagen fibers, which stabilizes the corneal structure and reduces further thinning and bulging.
How It Works
The standard CXL procedure, known as the Dresden protocol, involves two key steps:
- Riboflavin Application
A vitamin B2 solution (riboflavin) is applied to the cornea after the epithelium has been removed - a technique called "epi-off CXL." The riboflavin penetrates into the corneal stroma, making the tissue photosensitive and ready to respond to UV light activation.
- UV Light Exposure
The cornea is then exposed to UVA light at a wavelength of 365 nm for approximately 30 minutes. This UV light activates the riboflavin, generating reactive oxygen species (ROS) that form new cross-links between the collagen fibers in the corneal stroma.
Treatment Outcomes
CXL has proven highly effective in clinical practice. The treatment successfully halts disease progression in over 90% of cases, providing patients with significant long-term benefits. Some patients even experience mild improvements in corneal shape and visual acuity following the procedure. By stopping the progression of corneal ectasia, CXL helps delay or potentially avoid the need for corneal transplants, offering patients a less invasive alternative to maintain their vision.
Side Effects and Recovery
Common temporary effects include: Pain or discomfort, corneal haze, and blurry vision lasting from days to weeks
Rare complications may include: Infection, persistent corneal haze, delayed epithelial healing